SCHEMBL4215919

SCHEMBL4215919

COCOc1ccc(Cc2c(C)cc(CO)c(C)c2C)cc1C(C)C

nearest known ligand 0.39

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
THRB P10828 19/20 0.39
THRA P10827 17/20 0.39
RORC P51449 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4214209 0.90 THRB (0.38) THRBTHRA
SCHEMBL282571 0.86 THRB (0.46) THRBTHRA
SCHEMBL1457675 0.86 THRB (0.45) THRBTHRARORC
SCHEMBL282525 0.85 THRB (0.43) THRBTHRARORC
SCHEMBL25950186 0.84 THRB (0.36) THRBTHRARORC
SCHEMBL4962269 0.84 THRB (0.38) THRBTHRA
SCHEMBL3160766 0.82 THRB (0.45) THRBTHRA
SCHEMBL282106 0.82 THRB (0.48) THRBTHRA
SCHEMBL31041193 0.82 THRB (0.48) THRBTHRA
SCHEMBL282209 0.82 THRB (0.44) THRBTHRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090028925-A1 Novel Phosphinic Acid-Containing Thyromimetics METABASIS THERAPEUTICS, INC. 2009-01-29 US disclosed
EP-1890768-A2 NOVEL PHOSPHINIC ACID-CONTAINING THYROMIMETICS Metabasis Therapeutics, Inc. (US) 2008-02-27 EP disclosed
WO-2006128056-A2 NOVEL PHOSPHINIC ACID-CONTAINING THYROMIMETICS METABASIS THERAPEUTICS, INC. (US) 2006-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090028925-A1 Novel Phosphinic Acid-Containing Thyromimetics PYGL, PHOSPHO1, LIPE THRB 41/4885THRA 14/4885RORC 781/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.